View Older Stories View More Recent Stories

May 3, 2021 07:32AM ContraFect (CFRX) Announces Issuance of Composition of Matter Patent for CF-370 by the United States Patent and Trademark Office
May 3, 2021 07:30AM ContraFect Announces Issuance of Composition of Matter Patent for CF-370 by the United States Patent and Trademark Office
Apr 26, 2021 07:30AM ContraFect Invited to Participate in the Cystic Fibrosis Target Product Profile Virtual Symposium
Apr 15, 2021 06:30PM ContraFect Invited to Present at the Inaugural Anti-Infectives Drug Development Summit
Mar 30, 2021 07:30AM ContraFect Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update
Mar 11, 2021 04:08PM ContraFect (CFRX) Announces BARDA Contract Award for Up to $86.8 Million and Provides Business Outlook
Mar 11, 2021 04:05PM ContraFect Announces BARDA Contract Award for Up to $86.8 Million and Provides Business Outlook
Feb 11, 2021 07:00AM ContraFect Announces Appointment of Dr. Jane F. Barlow to Board of Directors
Nov 13, 2020 08:33AM ContraFect Reports Third Quarter 2020 Financial Results and Provides Business Update
Oct 26, 2020 07:00AM ContraFect Initiates Expanded Access to Exebacase for the Treatment of MRSA Bloodstream Infections in COVID-19 Patients
Sep 9, 2020 07:30AM ContraFect to Present at the 2020 Cantor Global Virtual Healthcare Conference
Aug 25, 2020 07:30AM ContraFect Announces Funding Agreement with the Cystic Fibrosis Foundation
Aug 14, 2020 07:30AM ContraFect Reports Second Quarter 2020 Financial Results and Provides Business Update
Jul 20, 2020 07:36AM UPDATE: ContraFect (CFRX) Reports Up to $18.9M in Funding from CARB-X to Accelerate CF-370 Program in IND-Enabling Activities Toward Future Ph. 1 Clinical Trials
Jul 20, 2020 07:30AM ContraFect Announces up to $18.9 Million in Funding from CARB-X to Support Acceleration of the CF-370 Program for Treating Pseudomonas aeruginosa Infections towards Clinical Stage Development
Jun 17, 2020 07:31AM ContraFect (CFRX) Reports Publication of Exebacase Phase 2 Study Results in the Journal of Clinical Investigation
Jun 17, 2020 07:30AM Contrafect Announces Publication of Exebacase Phase 2 Study Results in the Journal of Clinical Investigation
Jun 15, 2020 07:35AM ContraFect (CFRX) Names Lishan Aklog, M.D. to Board
Jun 15, 2020 07:30AM ContraFect Announces Appointment of Lishan Aklog, M.D. to Board of Directors
May 26, 2020 07:31AM ContraFect (CFRX) Announces Private Placement of Common Stock and Warrants to Pfizer
May 26, 2020 07:30AM ContraFect Corporation Announces Private Placement of Common Stock and Warrants to Pfizer Inc.
May 15, 2020 07:30AM ContraFect Reports First Quarter 2020 Financial Results and Provides Business Update
May 11, 2020 07:30AM ContraFect Announces Four Abstracts Published in the 30th ECCMID Abstract Book
Apr 21, 2020 07:00AM ContraFect Announces Dr. Roger J. Pomerantz, Chief Executive Officer and Chairman, Invited as Keynote Speaker and Presenter in Maxim’s Infectious Disease Virtual Conference
Mar 30, 2020 05:00AM ContraFect to Chair and Participate in Virtual Superbugs & Superdrugs 2020 Conference
Mar 18, 2020 07:00AM ContraFect Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Business Update
Mar 4, 2020 07:00AM ContraFect to Present at FDA Workshop on Advancing Animal Models for Antibacterial Drug Development
Feb 24, 2020 07:08AM ContraFect (CFRX) Gratned FDA Breakthrough Therapy Designation to Exebacase for the Treatment of MRSA Bacteremia, Including Right-Sided Endocarditis
Feb 24, 2020 07:00AM ContraFect Announces U.S. FDA Grants Breakthrough Therapy Designation to Exebacase for the Treatment of Methicillin-Resistant Staphylococcus aureus (MRSA) Bacteremia, Including Right-Sided Endocarditi
Feb 4, 2020 07:08AM ContraFect (CFRX) Announces 1-for-10 Reverse Stock Split
Feb 4, 2020 07:00AM ContraFect Announces One-for-Ten Reverse Stock Split
Feb 4, 2020 07:00AM ContraFect Announces One-for-Ten Reverse Stock Split
Feb 3, 2020 07:00AM ContraFect Appoints Jane E. Ambler, Ph.D. as Vice President of Clinical Microbiology
Feb 3, 2020 07:00AM ContraFect Appoints Jane E. Ambler, Ph.D. as Vice President of Clinical Microbiology
Jan 27, 2020 07:00AM ContraFect Announces Oral Presentations at the 30th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)
Jan 22, 2020 07:00AM ContraFect to Present at 2020 ASM Biothreats
Jan 13, 2020 08:00AM ContraFect Partners with Leading Orthopedic Center in Europe to Provide Compassionate Use of Exebacase to Patients with Chronic Staphylococcal Prosthetic Joint Infections
Jan 10, 2020 07:06AM ContraFect (CFRX) Reports First Patient Dosed in Pivotal Phase 3 DISRUPT Study of Exebacase
Jan 10, 2020 07:00AM ContraFect Announces First Patient Dosed in Pivotal Phase 3 DISRUPT Study of Exebacase as a Treatment for Staph aureus Bacteremia, Including Right-Sided Endocarditis
Jan 6, 2020 05:30PM ContraFect to Present at Biotech Showcase 2020
Dec 20, 2019 08:19AM ContraFect (CFRX) Commences Pivotal Phase 3 DISRUPT Study of Exebacase as Treatment for Staph Aureus Bacteremia, Including Right-Sided Endocarditis
Dec 20, 2019 08:00AM ContraFect Announces Initiation of Pivotal Phase 3 DISRUPT Study of Exebacase as a treatment for Staph aureus Bacteremia, Including Right-Sided Endocarditis
Dec 18, 2019 07:11AM ContraFect (CFRX) Announces First Gram-negative Product Candidate CF-370, Direct Lytic Agent Targeting Pseudomonas aeruginosa
Dec 18, 2019 07:00AM ContraFect Announces First Gram-negative Product Candidate CF-370, a Direct Lytic Agent Targeting Pseudomonas aeruginosa
Nov 29, 2019 09:00AM ContraFect to Present at the Piper Jaffray 31st Annual Healthcare Conference
Nov 12, 2019 07:00AM ContraFect Reports Third Quarter 2019 Financial Results and Provides Business Update
Nov 5, 2019 07:00AM ContraFect to Present at the World Anti-Microbial Resistance Congress 2019
Oct 2, 2019 07:06AM ContraFect (CFRX) Announces Plan for Single Phase 3 Superiority Design Study of Exebacase Following Successful End-of-Phase 2 Meeting with FDA
Oct 2, 2019 07:00AM ContraFect Announces Plan for a Single Phase 3 Superiority Design Study of Exebacase Following Successful End-of-Phase 2 Meeting with FDA
Oct 1, 2019 05:29PM ContraFect to Host Development Update Call and Webcast on October 2, 2019
View More Recent Stories View Older Stories